Helen Torley, PRESIDENT AND CEO at HALOZYME THERAPEUTICS, INC. (HALO), sold 109,000 shares at $71.28 ($7.8M) on 2025-10-02, disclosed to the SEC on 2025-10-03.
Scheduled sale ($7.8M) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $75.11 | 11,705 | $879K | 11.2% |
| 2 | $75.11 | 11,705 | $879K | 11.2% |
| 3 | $75.69 | 8,295 | $628K | 8.0% |
| 4 | $75.69 | 8,295 | $628K | 8.0% |
| 5 | $70.51 | 6,600 | $465K | 5.9% |
| 6 | $70.51 | 6,600 |
| $465K |
| 5.9% |
| 7 | $71.28 | 10,200 | $727K | 9.3% |
| 8 | $72.07 | 2,400 | $173K | 2.2% |
| 9 | $72.07 | 2,400 | $173K | 2.2% |
| 10 | $73.24 | 700 | $51K | 0.7% |
| 11 | $74.67 | 100 | $7K | 0.1% |
| 12 | $68.47 | 14,235 | $975K | 12.4% |
| 13 | $68.47 | 14,235 | $975K | 12.4% |
| 14 | $69.83 | 2,334 | $163K | 2.1% |
| 15 | $69.83 | 2,334 | $163K | 2.1% |
| 16 | $70.58 | 2,707 | $191K | 2.4% |
| 17 | $70.58 | 2,707 | $191K | 2.4% |
| 18 | $71.67 | 724 | $52K | 0.7% |
| 19 | $71.67 | 724 | $52K | 0.7% |
| Total | $71.91 avg | 109,000 | $7.8M | 100% |
| Filing → |
| HALO | SELL | 2026-08-19 | $6.3M | — | Filing → |
| HALO | SELL | 2026-07-09 | $153K | — | Filing → |
| HALO | SELL | 2026-06-03 | $3.4M | — | Filing → |